Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALLO-ASC-BI
- Development stage
- Unknown
- Lead developer
- Anterogen
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Topical
01
Overview
ALLO-ASC-BI is an allogeneic cell therapy developed by Anterogen Co., Ltd., consisting of adipose-derived mesenchymal stem cells (ASCs). It is specifically designed for the treatment of burn injuries. The therapy is typically formulated as a hydrogel sheet for topical application to the wound site. The mechanism of action involves the secretion of various cytokines and growth factors that promote angiogenesis, modulate the inflammatory response, and accelerate tissue regeneration and wound healing. Clinical evaluation has progressed to Phase 2 trials (e.g., ALLO-ASC-BI-201).
- Other names
- allogeneic adipose-derived mesenchymal stem cells
Beyond the preview
Go deeper on ALLO-ASC-BI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALLO-ASC-BI.